Compare Moderna, Inc. (MRNA) vs GraniteShares 2x Long NVDA Daily ETF (NVDL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs GraniteShares 2x Long NVDA Daily ETF — how do they compare? Moderna, Inc. trades at $225 (market cap $78.65B), while GraniteShares 2x Long NVDA Daily ETF trades at $36.86 (market cap $3.56B). The key difference: Moderna, Inc. is far larger — about 22.1× GraniteShares 2x Long NVDA Daily ETF's market cap, and Moderna, Inc. is trading nearer its 52-week high, GraniteShares 2x Long NVDA Daily ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and GraniteShares 2x Long NVDA Daily ETF for 15 Days on average.
| MRNA | NVDL | |
|---|---|---|
Market Cap | $78.65B | $3.56B |
Volume | 37,373,437 | 9,740,643 |
Sector | Health | Leveraged / Inverse |
52-Week High | $225.00 | $43.02 |
52-Week Low | $22.36 | $21.76 |
Typical Hold Time | 59 Days | 15 Days |
Enterprise Value | $74.80B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $197.00, up 0.26% on the day, with technical indicators showing a bullish trend and strong momentum. The stock has rallied over 500% in 2026, driven by positive clinical updates for its cancer vaccine pipeline and inclusion in the Nasdaq-100 index effective October 9, 2026. However, fundamentals remain challenging with revenue declining from $18.9B in 2022 to $1.9B in 2025 and negative net income margins exceeding 140%.
While technical momentum and pipeline optimism support near-term upside, valuation appears stretched with P/S of 35.08 and negative profitability metrics. Key risks include execution on non-COVID products, competitive pressure, and sustainability of recent gains. Analyst consensus is cautious with only 28% buy ratings and $115.70 price target suggesting significant downside from current levels.
NVDL (GraniteShares 2x Long NVDA Daily ETF) trades at $37.28, down 5.79% in the last session. Technical indicators show a bullish bias with moving averages supporting upward momentum while oscillators remain neutral. The ETF provides 2x daily leveraged exposure to NVIDIA, which continues to dominate AI chip markets with strong earnings performance. Recent news highlights ongoing M&A activity in the ETF space and continued AI sector strength.
The outlook remains positive given NVIDIA's market leadership and AI growth trajectory, though leveraged ETF structure introduces volatility risks. Key opportunities include continued AI adoption and NVIDIA's execution, while risks involve leverage decay and sector concentration. Current technical setup suggests potential for recovery toward resistance levels near $39-41 if bullish momentum resumes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About GraniteShares 2x Long NVDA Daily ETF
NVDL is a leveraged ETF that seeks daily investment results corresponding to 200% (2x) of the daily performance of NVIDIA Corporation (NVDA) stock. It is designed as a tactical trading tool for investors with a strong bullish (long) view on NVDA. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from two times the performance of the NVDA stock.
Read more on NVDL →
